跳至主要内容
临床试验/NCT04365673
NCT04365673终止不适用

Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study

Tabula Rasa HealthCare1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年7月7日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
100
试验地点
1
主要终点
Readmission

研究概览

简要总结

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

详细描述

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 88 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

排除标准

  • 89 years or older

结局指标

主要结局

Readmission

时间窗: 2018 - 2019

Readmission within 30-days post hospital discharge

次要结局

未报告次要终点

研究者

发起方
Tabula Rasa HealthCare
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

LACE+ and MRS Score Readmission Rate Assessment | 临床试验